Effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on murine bone marrow and spleen erythropoiesis.
Acta Physiol Pharmacol Ther Latinoam
; 48(1): 18-24, 1998.
Article
em En
| MEDLINE
| ID: mdl-9504189
100 micrograms/kg of recombinant human granulocyte colony-stimulating factor was injected twice daily into normal adult CF1 female mice for a period of 15 days. After that time we have observed a decrease 59Fe marrow incorporation with a parallel increase in the spleen. During the first 9 days the marrow plus spleen erythroid cells number decreased to 60% of control approximately, but recovered thereafter and were not significantly different from normal values at 12-15 days. In addition, our studies demonstrate that the spleen erythropoiesis is quantitatively more important at the final time than marrow erythropoiesis. For this reason, splenic compensatory erythropoiesis maintained the hematocrit values between normal ranges. Regarding the granulocytic compartment, 15 days of rhG-CSF treatment produce a marked increase in total count of splenic granulocytes (a 7.7 fold rise from control values). Marrow granulocytes shows a 2-fold increment, but considering the absolute counts, bone marrow still was predominant as a granulopoieitc organ. Our results indicate that the spleen is a more important erythropoietic organ than marrow after 15 days of rhG-CSF treatment.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Baço
/
Medula Óssea
/
Fator Estimulador de Colônias de Granulócitos
/
Eritropoese
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Acta Physiol Pharmacol Ther Latinoam
Assunto da revista:
FARMACOLOGIA
/
FISIOLOGIA
/
TERAPEUTICA
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Argentina
País de publicação:
Argentina